The validated health assessment questionnaire (HAQ) such as the RAPID3, gives the rheumatologist the opportunity to have a more frequent and objective view on the effectivity and safety of the treatment. There is a relation between the RAPID3 and…
ID
Bron
Aandoening
Patient Reported Outcomes, PROs
Rheumatoid Arthritis, RA
Intensive outpatient management
Tight Control
Treat to target (T2T)
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Patient reported outcomes (RAPID-3) and DAS28
Achtergrond van het onderzoek
This is a prospective observational study, addressing the relationship between DAS28 scores and RAPID3 questionnaires during the treatment of rheumatoid arthritis in adults. Four rheumatologists each assessed patients with rheumatoid arthritis in “real time” clinical care. The rheumatologist or nurse practioner performed a 28-joint count. Patients,recruited in the Netherlands, are emailed and asked to complete the RAPID3 questionnaire. The questionnaire takes 5-10 minutes to complete. The performed RAPID3 will be compared with the DAS28 on a 0-30 versus 1-10 scale. Scores are classified as high activity, moderate activity, low activity, and remission according to the DAS28 and RAPID3 scores. The DAS28 and RAPID3 scores will be statistically compared with a spearman’s rank correlation and with Cohen's kappa coefficient. The questionnaire is processed by an online data portal, which is protected and certified with ISO 9001/ ISO 27001.
Doel van het onderzoek
The validated health assessment questionnaire (HAQ) such as the RAPID3, gives the rheumatologist the opportunity to have a more frequent and objective view on the effectivity and safety of the treatment. There is a relation between the RAPID3 and the DAS28 in clinical practice.
Onderzoeksopzet
% with Routine Assessment of Patient Index Data with 3 measures (RAPID3) Timepoints: 4 times a year. % with Disease Activity Score in 28 joints (DAS28) Timepoints: 4 times a year.
Onderzoeksproduct en/of interventie
N/A
Publiek
[default]
The Netherlands
Wetenschappelijk
[default]
The Netherlands
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Adults with reumatoïde artritis treated with biologicals, such as TNFα-blockers (etanercept, adalimumab, infliximab etc.), interleukine-I-blockers, the B-celblocker rituximab, and the T-celactivationblocker and anti CTLA4 (abatacept).
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
non RA patients, no biological treatment, non adult,
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL3983 |
NTR-old | NTR4155 |
Ander register | METC ATRIUM ORBIS ZUYD : 13-N-100 |
ISRCTN | ISRCTN wordt niet meer aangevraagd. |